Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Endocrine & Metabolic Disease Models

Endocrine & Metabolic Disease Models

In the field of metabolic diseases, we have a portfolio of stable and effective animal models, including for Non-alcoholic Fatty Liver Disease (NAFLD).
Download
  • DiseaseTypeSpecies
    DiabetesModel of type 1 diabetes induced by streptozotocinMouse/Rat
    Spontaneous type 2 diabetes mice (db/db, ob/ob)db/db, ob/ob Mouse
    Spontaneous type 2 diabetes rat (ZDF)Zucker Rat
    Diabetic skin ulcer modelMouse/Rat
    Diabetic foot modelMouse/Rat
    HyperuricemiaPotassium oxonate inducedRat/Mouse
    Adenine+potassium oxonate inducedRat
    Uric acid inducedMouse
    Hypoxanthine inducedMouse
    Adenine + ethambutol inducedRat
    Yeast inducedMouse
    DiseaseTypeSpecies
    Liver FibrosisBiliary ligation inducedRat
    TAA-inducedRat
    Composite factor method inducedRat
    ConA inducedMouse
    Immune liver fibrosis caused by pig serumRat
    NAFLD(NAFL / NASH)HFD diet inducedMouse/Rat/Hamster
    MCD diet inducedMouse
    CDAA diet inducedRat
    Composite factor inducedRat
    DyslipidemiaHereditary atherosclerosisAPOE Mouse
    High fat / cholesterol / fructose diet inducedRat/Hamster
Service Cases

  Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing.webp

Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing

Learn More

 Medicilon Assist – New progress in the field of NASH! Hepadin's HPD001 is about to start clinical trials in the U.S..webp

Medicilon Assist – New progress in the field of NASH! Hepadin's HPD001 is about to start clinical trials in the U.S.

Learn More

       Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610.webp

Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610

Learn More

For more service cases, please contact us:

Leave a message

FAQ
  • What is the Difference Between NAFL and NASH?

    NAFL:

    It is completely reversible and can be completely reversed through a healthy lifestyle such as diet and exercise controlling diet, exercise and other healthy lifestyles. Drug therapy is mainly to improve lipid metabolism.

    NASH:

    It is a progressive form of nonalcoholic fatty liver disease, a metabolically stressful metabolic stress liver injury closely associated with insulin resistance and genetic predisposition, can progress to cirrhosis and hepatocellular carcinoma. It was also significantly associated with an increased risk of cardiovascular disease.

    The etiology of NASH is complex, and the exact pathogenesis is unknown. There is no specific treatment or drug therapy for Nash.

    NASH treatment drugs with different targets have become one of the current research and development hotspots, which target the different pathogenesis of NASH, such as liver metabolism, inflammation, oxidative stress, fibrosis, etc.

Relevant laboratories
  • LC/MS
  • centrifuge
  • Pathological observation
  • pathological section
  • frozen slice
  • high-speed centrifuge
  • SPE
  • Liquid analysis laboratory
  • Pharmaceutical laboratory
  • Inspection equipment
  • Immunoassay Platform
Relevant articles